Keith Richardson
Papers
5
Total Citations
519
H-Index
4
About
Keith Richardson is a head and neck oncology researcher whose work has significantly shaped the treatment landscape for oropharyngeal squamous cell carcinoma (OPSCC), particularly in the era of HPV-associated disease. His research sits at the intersection of surgical innovation, radiation oncology, and patient-centered outcomes, with a sustained focus on optimizing treatment while preserving quality of life. Richardson is perhaps best known for his involvement in the landmark ORATOR trial, a phase 2 randomized study comparing radiotherapy with transoral robotic surgery (TORS) and neck dissection for OPSCC. Published in 2019 and accumulating over 458 citations, this pivotal work provided the field with rare prospective comparative data between two curative-intent modalities. The trial's five-year final results, published in 2024, further cemented its clinical relevance. A recurring theme throughout Richardson's career is treatment deintensification for HPV-positive patients—reducing toxic side effects without compromising oncologic control. His investigations into neoadjuvant chemotherapy combined with TORS reflect this ambition, examining both distant metastasis risk and patient-reported quality of life outcomes. Collectively, his contributions have helped redefine surgical and multimodal approaches to a cancer type whose incidence continues to rise globally.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5